Does Long-Term Oral GABA Restore Beta-Cell Function in Long-Standing Type 1 Diabetes?
A phase I/II randomized trial found long-term controlled-release oral GABA (Remygen) did not improve C-peptide, CGM metrics, or HbA1c in men with long-standing type 1 diabetes, and side effects were common. PICO summary and expert commentary.
